2023 Guidance and Q3 Earnings

Bepirovirsen a triple-action antisense oligonucleotide Providing patients with a potential functional cure for chronic hepatitis B B-Together: positive phase IIb results demonstrated proof of concept Hepatitis B virus >300 million people living with HBV1 . Viral infection of the liver that can cause both acute and chronic liver disease² Chronic Hepatitis B (CHB) is a long- lasting infection and occurs when the body's immune system is unable to fight off the virus and it persists in the blood and liver³ Diagnosis rates remain low - in US and Europe only ~25% of infections are diagnosed. Even when treated, cure rates are very low. Proportion of participants with response to treatment, % All (N=108) Baseline HBsAg ≤3000 IU/mL (N=68) Baseline HBsAg ≤1000 IU/mL (N=34) 80 70 60 50 40 30 20 20 10 O Peg-IFN EOT virologic (Week 48) 24 weeks post end of sequential EoT (Week 72) BPV EoT virologic response (Week 12) Peg-IFN EOT virologic response (Week 36) response BPV EoT virologic response (Week 24) 24w BPV+24w Peg-IFN 12w BPV + 24w Peg-IFN 24 weeks post end of sequential EOT (Week 60) H2 2023: B-Sure long-term durability of sustained virologic response data presented as a late-breaking abstract at AASLD GSK 2. World Health Organization. Hepatitis B. Accessed October 2023. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b 1. Hepatitis B virus Hepatitis Report, 2017 3. World Health Organization. Global 11

View entire presentation